Journal
TRENDS IN GENETICS
Volume 30, Issue 10, Pages 464-474Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tig.2014.07.005
Keywords
TET; 5-hydroxymethylcytosine; 5mC; 5hmC; DNA methylation; DNA demethylation; cancer; IDH; OGT
Categories
Funding
- NIH [HD065812, AI44432, CA151535]
- California Institute for Regenerative Medicine [RM1-01729]
- Leukemia Society of America [6187-12]
Ask authors/readers for more resources
DNA methylation has been linked to aberrant silencing of tumor suppressor genes in cancer, and an imbalance in DNA methylation demethylation cycles is intimately implicated in the onset and progression of tumors. Ten-eleven translocation (TET) proteins are Fe(II)- and 2-oxoglutarate (20G)-dependent dioxygenases that successively oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), thereby mediating active DNA demethylation. In this review, we focus on the pathophysiological role of TET proteins and 5hmC in cancer. We present an overview of loss-of-function mutations and abnormal expression and regulation of TET proteins in hematological malignancies and solid tumors, and discuss the potential prognostic value of assessing TET mutations and 5hmC levels in cancer patients. We also address the crosstalk between TET and two critical enzymes involved in cell metabolism: O-linked beta-N-acetylglucosamine transferase (OGT) and isocitrate dehydrogenase (IDH). Lastly, we discuss the therapeutic potential of targeting TET proteins and aberrant DNA methylation in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available